fashion -WSS

fashion

author：explore 2025-09-29 16:45:34 - browse：7

The Food and Drug Administration on Friday approved a new, rapid-acting medicine made by Sage Therapeutics to treat postpartum depression, the first oral treatment for the condition. But the agency denied the company’s application for an indication for major depression, a much larger potential market.

The drug, which will be sold under the brand name Zurzuvae, is not meant to be taken chronically. Patients take it orally for 14 days. In two clinical trials, the drug was found to significantly improve depressive symptoms more than a placebo. The effect was maintained for four weeks after treatment.

“Maternal mental health has been sidelined for far too long, but today’s approval of Zurzuvae helps to change that. Women have been waiting for an oral medicine that can specifically and rapidly improve the symptoms of PPD and we are proud to be able to deliver that,” said Barry Greene, Sage’s CEO, in a press release.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： What does generative AI mean for health care? We asked experts
Next article： Microbiome research is starting to find links to chronic diseases

WSS

Medical student insurance fails on mental health care coverage

Medtronic CEO on promising devices for diabetes, hypertension

Biotech stock slump in 2023: awaiting the turnaround

CDC advisers recommend seasonal use of Pfizer RSV shot

It's been 20 years since Dolly the sheep. Where's my clone?

Thermo Fisher plant for manufacturing gene therapies to expand

focus

fashion

hotspot

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

FDA panel to weigh approval of NurOwn, controversial ALS drug

Peter Hotez and the public health issue of online harassment

Changes to biosimilar regulatory framework must prioritize patients

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Eli Lilly to pay $200M for Beam’s stake in gene

At least 13 dead in Texas as scorching temps continue

An exit interview with Bristol Myers Squibb CEO Giovanni Caforio

Medical leaders decry Supreme Court decision on affirmative action

Emergency workers more likely to restrain Black patients: study

entertainment

FDA panel to weigh approval of NurOwn, controversial ALS drug

Cassava reveals details — and problems — with Alzheimer's study

Chimpanzees, like humans and whales, get menopause: Study

Lasker Awards 2023: Winners in biomedical research

Changes to biosimilar regulatory framework must prioritize patients

An exit interview with Bristol Myers Squibb CEO Giovanni Caforio

hotspot

hotspot

focus

hotspot